SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. - Wikidata - awgldk - TriplyDB

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.

http://www.wikidata.org/entity/Q36376264

about

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Gallbladder Cancer in the 21st Century.Targeted Therapy in Biliary Tract Cancers Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis Optimum chemotherapy for the management of advanced biliary tract cancer Progression of targeted therapy in advanced cholangiocarcinoma Targeted therapy in biliary tract cancers-current limitations and potentials in the future.Targeting Angiogenesis in Biliary Tract Cancers: An Open Option The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma.Systemic Therapy of Cholangiocarcinoma.Prognostic value of neutrophil distribution in cholangiocarcinoma.Perioperative Management of Hilar Cholangiocarcinoma.Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management.HOXD10 acts as a tumor-suppressive factor via inhibition of the RHOC/AKT/MAPK pathway in human cholangiocellular carcinoma Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.Current status of chemotherapy for the treatment of advanced biliary tract cancer.Current therapy and future directions in biliary tract malignancies.EF24 inhibits tumor growth and metastasis via suppressing NF-kappaB dependent pathways in human cholangiocarcinoma.Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma.S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.Multidisciplinary approaches to intrahepatic cholangiocarcinoma.New and emerging treatment options for biliary tract cancer.Multimodal treatment strategies for advanced hilar cholangiocarcinoma.Emerging molecular targets and therapy for cholangiocarcinoma.Cholangiocellular Carcinoma.Novel investigational therapies for treating biliary tract carcinoma.Intrahepatic cholangiocarcinoma: current management and emerging therapies.Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications.Current biologics for treatment of biliary tract cancers.Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy.

P2860

Q26751224-4D70F843-73E7-4C5C-A018-C3D6E58EC449 Q26784174-AFE142A6-3A7C-4924-8A9B-7568569DF80F Q26798443-FE950B6B-E230-4FDE-8502-E7FE4F2E09EC Q27002547-123067DF-9F00-4112-8113-B3709595A79A Q27003304-7F3EFA37-5191-4AB5-9659-7160776A1308 Q27010873-928188F5-0F40-4BCA-A4D2-E554C43F82EC Q27016150-A4099A72-BE34-431A-B8B6-D45103829576 Q30234532-3B15E440-15FC-4498-8937-64960822F18F Q30398807-B8039FA1-CCCC-4DA9-A9AC-94569DE3E38A Q33441341-C0D8C161-3DF1-4DF2-B644-650902A53102 Q33686690-F42E0B54-05CF-4DC5-A51C-F98D7A9234D8 Q34551877-C8582931-DF62-4330-8183-FE76A4D1182B Q35534078-1046A896-19FB-4C02-982E-B05B51A8039C Q35645739-CEA14867-9DAE-4FEB-89A4-FF5D5C74EDC9 Q35674607-32EEF8B2-0852-4C94-A7F8-C3D560CF102B Q36041680-2007DEEF-A7BC-4337-8E5D-27B43173793D Q36113790-80A598AF-E517-4225-8BF0-BAB4DB52E33E Q36270115-3E78717C-0090-4EDA-B81E-0DE49DBADFD1 Q36683019-4203C448-FFDD-48EF-92BC-AE022722211D Q36822722-0B605731-B4D6-411D-89C4-FAFD744BA639 Q36962011-FCB5D366-500E-4984-8975-438EE7198660 Q37017110-F0D7E0D3-9B6D-44F2-935E-F784240B26A9 Q37111209-EDD095EF-BDB2-4A25-8E65-0A5353F0AC5F Q37138732-78E07D1C-254D-4252-AD10-C6D9F59E6912 Q37161293-8AC4C0C8-B575-4681-88B6-944406B67682 Q37215717-E2897DBE-8F74-49C4-A3F6-5083B8C6337F Q37536010-21EBD178-739D-47F4-B876-1F12F9527664 Q37594373-393441AF-29A2-4B6B-A5AB-79E3C679BE19 Q37719383-4ECE4841-82E3-4584-9632-9AE13A0F4257 Q37725603-06CD4393-5DD7-490D-885D-054A854D5EF8 Q38130469-A0E88C3A-EB76-4226-82D2-64240F9D9C95 Q38160836-3B39D1AA-1F0E-4502-B4DA-7A289A48E8E0 Q38222988-F694D2AF-B389-4C99-B88C-B2535595CAAB Q38642455-ACD42869-D72A-49EC-B2AD-20A70D682710 Q38746546-805FFC78-383D-4E89-AA83-7C8EF97C327B Q38799963-845DB352-B682-42FB-B4C3-7771F1449AE4 Q39186928-AE8C7661-553B-4C22-BF50-31CEBA8A26DB Q39289707-24950727-9A44-4E98-855A-EB29E14CA12A Q39453572-B6ED76A9-27F9-4982-B32D-5D6F785DABCB Q39995898-6232A60B-08C5-4D29-84EF-F32D1B69EBCC

P2860

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.

http://www.wikidata.org/entity/Q36376264

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

SWOG 0514: a phase II study of ...... cinoma and cholangiocarcinoma.

@ast

SWOG 0514: a phase II study of ...... cinoma and cholangiocarcinoma.

@en

type

label

SWOG 0514: a phase II study of ...... cinoma and cholangiocarcinoma.

@ast

SWOG 0514: a phase II study of ...... cinoma and cholangiocarcinoma.

@en

prefLabel

SWOG 0514: a phase II study of ...... cinoma and cholangiocarcinoma.

@ast

SWOG 0514: a phase II study of ...... cinoma and cholangiocarcinoma.

@en

P1433

Q36376264-4F8D16BF-DF38-4016-93DC-BDA4FBFC343F

P1476

Q36376264-CCB3A79A-0742-4516-8505-AF8FE8A69049

P2093

Q36376264-2220695E-C7F0-46E6-A0F1-DBB6FA223BF6

Q36376264-4EAF15EA-5811-41FF-A48A-6F0D96EAD038

Q36376264-BF155F5A-83CF-4012-A1BC-962388C8DDF2

Q36376264-D50968AD-4EFD-4C2E-AB9F-970C7F6450AE

Q36376264-DDC031EF-9D90-4590-A6B7-8C98C90E743A

Q36376264-E3CFFEB1-6FA5-41A5-B485-55973E7EE225

Q36376264-E695AFEB-3F17-4AC6-95E6-A5779C82706C

P2860

Q36376264-0796BE18-20D9-4FA4-86ED-5D47388B3F5E

Q36376264-0F3424E1-7B89-46EC-9640-892B98507030

Q36376264-110EAAFC-82A0-4366-AD16-3AB67FAC6208

Q36376264-196C81A2-8D07-4EAA-AA8B-975CF4FBFCCC

Q36376264-2EF79E02-095F-4084-AA60-E8287EFDCC44

Q36376264-598892CF-3968-4C75-A073-7491B870A940

Q36376264-740B2D56-BC6D-45F1-AA67-8DE48026359C

Q36376264-94449BAD-AC66-4F13-8AC0-1268AD3D786A

Q36376264-9F5EACA9-D134-46D1-A9E4-05090D03B61C

Q36376264-AE0609AD-96B5-4FDE-A052-0D83FFA3063E

P2888

Q36376264-B66D87E1-6969-4452-90EF-208D832863DB

P304

Q36376264-FE85F348-45E3-42EA-8A52-DE13F1DE1FDB

P31

Q36376264-EE82D46F-ACC5-408E-B7BF-68F099327021

P356

Q36376264-2BA6DD71-51F4-47E1-80AE-47163B6A3CCF

P433

Q36376264-5E7D70F0-231A-418E-BC9F-EE3CAD68A356

P478

Q36376264-27B65A41-5E18-4B17-8403-11FCF3607A9A

P50

Q36376264-7F2A1EB5-2FDB-414C-8508-91D3CD35AF75

Q36376264-B3B97A93-C675-4989-8FC9-FCF432267E85

P577

Q36376264-68001B6C-A00F-478B-8813-CA5767352604

P698

Q36376264-832C9923-923A-46FA-8F9D-007679038579

P921

Q36376264-90296336-6659-44A2-BFD6-FC3F45F8C2A2

P932

Q36376264-C4D78C48-CF03-4678-AF51-FF648FC8EE4D

P356

S10637-011-9719-0

P1433

Investigational New Drugs

P1476

SWOG 0514: a phase II study of ...... cinoma and cholangiocarcinoma.

@en

P2093

Anthony B El-Khoueiry

http://www.w3.org/2001/XMLSchema#string

Cathryn J Rankin

http://www.w3.org/2001/XMLSchema#string

Cathy Eng

http://www.w3.org/2001/XMLSchema#string

Charles D Blanke

http://www.w3.org/2001/XMLSchema#string

Philip J Gold

http://www.w3.org/2001/XMLSchema#string

R Darryl Hamilton

http://www.w3.org/2001/XMLSchema#string

Rangaswamy Govindarajan

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in advanced hepatocellular carcinoma

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.

Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors.

A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

P2888

s10637-011-9719-0

P304

1646-1651

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-011-9719-0

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Edgar Ben-Josef

Heinz-Josef Lenz

P577

2011-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21748296

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

3490705

http://www.w3.org/2001/XMLSchema#string